E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Postoperative pain after colon rectal cancer surgery are mainly intended to relieve as well resting as activity-induced pain. Secondarily, the choice of pain management should take into consideration how to ensure the earliest possible mobilization and rapid fluid and food intake. There are now some evidence in laparoscopic gastrointestinal surgery that supports that perioperative infusion of lidocaine intravenously can reduce opioid consumption and length of postoperative ileus.
|
|
E.1.1.1 | Medical condition in easily understood language |
Pain after colon rectal cancer surgery is common. By this experiment we wish to provide better pain relief by providing a local anesthetic(lidocaine) in a vein during colon rectal cancer surgery. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018017 |
E.1.2 | Term | Gastrointestinal tract cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main purpose of the trial is to investigate whether intravenous lidocaine administered perioperatively can significantly reduce postoperative morphine consumption during the first 24 hours postoperatively by robot-assisted laparoscopic colon rectal cancer surgery.
|
|
E.2.2 | Secondary objectives of the trial |
Secondarily, we will examine whether this administration also significantly reduces morphine consumption up to 72 hours and reduces the duration of post-operative gastrointestinal dysfunction including reducing the incidence of post-operative nausea and vomiting as compared to placebo. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients undergoing robotic assisted laparoscopic colon rectal cancer surgery and giving their informed consent to participate in the trial. Age ≥ 18years of age. Danish-speaking patient. |
|
E.4 | Principal exclusion criteria |
Known hypersensitivity to the drug or local anesthetics of the amide type
AV block
Hepatic or renal impairment (ALT, AST, Bili> 2.5 x upper limit and CrCl <60ml / min)
Durable consumption of opioids and NSAIDs
Pregnancy or women of childbearing age without adequate contraception, breastfeeding women.Pregnancy test must be negative.
Treatment with beta blockers
Patients with known porphyria
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Reduction in pain intensity after the operation in terms of reduction in morphine consumption during the first 24 hours postoperatively. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The first 24 hours postoperatively for each patient included in the trial. |
|
E.5.2 | Secondary end point(s) |
Reduction in numerical rating scale (NRS), compared to placebo.
Reduction in the duration of postoperative gastrointestinal dysfunction including a reduction in the consumption of anti-emetic therapy, as well as reduction in morphine consumption up to 72 hours postoperatively.
Incidence of adverse reactions to the study drug are also recorded, if present. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
72 hours postoperatively for each patient included in the trial. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
60 patients for robotic assisted laparoscopic colon rectal cancer surgery are to be included in the trial. The trial will be completed when the calculated number of patients are included and followed up in 72 hours. The trial also be terminated if new, unexpected knowledge that make it dangerous to participate in the trial turns out. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |